Learn more about the microbiology of DORIBAX®
- Consistently low MIC90 values for P aeruginosa – results from the TRUST 10-13 Surveillance Studies*
- Low MICs against P aeruginosa isolates of concern – results from the CAPITAL Program*
- Cumulative In Vitro Inhibition of P aeruginosa*
- The distinct Molecular Structure of DORIBAX®
*In vitro activity does not necessarily correlate with clinical results; not intended to convey comparative safety or efficacy.
Please see Select Usage Information below.
Select Usage Information
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX® and other antibacterial drugs, DORIBAX® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy